157 related articles for article (PubMed ID: 9779701)
1. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.
Liu SY; Eary JF; Petersdorf SH; Martin PJ; Maloney DG; Appelbaum FR; Matthews DC; Bush SA; Durack LD; Fisher DR; Gooley TA; Bernstein ID; Press OW
J Clin Oncol; 1998 Oct; 16(10):3270-8. PubMed ID: 9779701
[TBL] [Abstract][Full Text] [Related]
2. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
Gopal AK; Rajendran JG; Gooley TA; Pagel JM; Fisher DR; Petersdorf SH; Maloney DG; Eary JF; Appelbaum FR; Press OW
J Clin Oncol; 2007 Apr; 25(11):1396-402. PubMed ID: 17312330
[TBL] [Abstract][Full Text] [Related]
3. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study.
Behr TM; Griesinger F; Riggert J; Gratz S; Béhé M; Kaufmann CC; Wörmann B; Brittinger G; Becker W
Cancer; 2002 Feb; 94(4 Suppl):1363-72. PubMed ID: 11877767
[TBL] [Abstract][Full Text] [Related]
4. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.
Kaminski MS; Zasadny KR; Francis IR; Fenner MC; Ross CW; Milik AW; Estes J; Tuck M; Regan D; Fisher S; Glenn SD; Wahl RL
J Clin Oncol; 1996 Jul; 14(7):1974-81. PubMed ID: 8683227
[TBL] [Abstract][Full Text] [Related]
5. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
Press OW; Eary JF; Appelbaum FR; Martin PJ; Badger CC; Nelp WB; Glenn S; Butchko G; Fisher D; Porter B
N Engl J Med; 1993 Oct; 329(17):1219-24. PubMed ID: 7692295
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.
Press OW; Eary JF; Appelbaum FR; Martin PJ; Nelp WB; Glenn S; Fisher DR; Porter B; Matthews DC; Gooley T
Lancet; 1995 Aug; 346(8971):336-40. PubMed ID: 7623531
[TBL] [Abstract][Full Text] [Related]
8. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
Kaminski MS; Fig LM; Zasadny KR; Koral KF; DelRosario RB; Francis IR; Hanson CA; Normolle DP; Mudgett E; Liu CP
J Clin Oncol; 1992 Nov; 10(11):1696-711. PubMed ID: 1403053
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.
Kaminski MS; Zasadny KR; Francis IR; Milik AW; Ross CW; Moon SD; Crawford SM; Burgess JM; Petry NA; Butchko GM
N Engl J Med; 1993 Aug; 329(7):459-65. PubMed ID: 7687326
[TBL] [Abstract][Full Text] [Related]
10. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience.
Wahl RL; Zasadny KR; MacFarlane D; Francis IR; Ross CW; Estes J; Fisher S; Regan D; Kroll S; Kaminski MS
J Nucl Med; 1998 Aug; 39(8 Suppl):21S-27S. PubMed ID: 9708567
[TBL] [Abstract][Full Text] [Related]
11. Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.
Wagner JY; Schwarz K; Schreiber S; Schmidt B; Wester HJ; Schwaiger M; Peschel C; von Schilling C; Scheidhauer K; Keller U
Oncotarget; 2013 Jun; 4(6):899-910. PubMed ID: 23765188
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.
Press OW; Eary JF; Gooley T; Gopal AK; Liu S; Rajendran JG; Maloney DG; Petersdorf S; Bush SA; Durack LD; Martin PJ; Fisher DR; Wood B; Borrow JW; Porter B; Smith JP; Matthews DC; Appelbaum FR; Bernstein ID
Blood; 2000 Nov; 96(9):2934-42. PubMed ID: 11049969
[TBL] [Abstract][Full Text] [Related]
13. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
Buchmann I; Bunjes D; Kotzerke J; Martin H; Glatting G; Seitz U; Rattat D; Buck A; Döhner H; Reske SN
Cancer Biother Radiopharm; 2002 Apr; 17(2):151-63. PubMed ID: 12030109
[TBL] [Abstract][Full Text] [Related]
14. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
15. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
16. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.
Gopal AK; Gooley TA; Maloney DG; Petersdorf SH; Eary JF; Rajendran JG; Bush SA; Durack LD; Golden J; Martin PJ; Matthews DC; Appelbaum FR; Bernstein ID; Press OW
Blood; 2003 Oct; 102(7):2351-7. PubMed ID: 12750161
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.
Kaminski MS; Estes J; Zasadny KR; Francis IR; Ross CW; Tuck M; Regan D; Fisher S; Gutierrez J; Kroll S; Stagg R; Tidmarsh G; Wahl RL
Blood; 2000 Aug; 96(4):1259-66. PubMed ID: 10942366
[TBL] [Abstract][Full Text] [Related]
18. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Knox SJ; Goris ML; Trisler K; Negrin R; Davis T; Liles TM; Grillo-López A; Chinn P; Varns C; Ning SC; Fowler S; Deb N; Becker M; Marquez C; Levy R
Clin Cancer Res; 1996 Mar; 2(3):457-70. PubMed ID: 9816191
[TBL] [Abstract][Full Text] [Related]
19. Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.
Gopal AK; Gooley TA; Rajendran JG; Pagel JM; Fisher DR; Maloney DG; Appelbaum FR; Cassaday RD; Shields A; Press OW
Biol Blood Marrow Transplant; 2014 Jun; 20(6):770-5. PubMed ID: 24530971
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
Leahy MF; Seymour JF; Hicks RJ; Turner JH
J Clin Oncol; 2006 Sep; 24(27):4418-25. PubMed ID: 16940276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]